Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Pipeline Review, H1 2016', provides in depth analysis on Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted pipeline therapeutics. The report provides comprehensive information on the Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - The report reviews Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects - The report assesses Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) Overview 6 Therapeutics Development 7 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Stage of Development 7 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Therapy Area 8 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Indication 9 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Companies 12 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Companies Involved in Therapeutics Development 20 AGV Discovery, SAS 20 Genentech, Inc. 21 Kura Oncology, Inc. 22 Laurent Pharmaceuticals Inc. 23 Merck & Co., Inc. 24 Merck KGaA 25 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Drug Profiles 26 CB-745 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 fenretinide - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 KO-947 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 RG-7842 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 SCH-722984 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 sprifermin - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ulixertinib - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Dormant Projects 34 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Discontinued Products 35 Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Featured News & Press Releases 36 Jun 15, 2015: Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis 36 May 20, 2014: Laurent Pharmaceuticals announces initiation of a Phase 1 clinical study of Fenretinide in Cystic Fibrosis 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by AGV Discovery, SAS, H1 2016 20 Pipeline by Genentech, Inc., H1 2016 21 Pipeline by Kura Oncology, Inc., H1 2016 22 Pipeline by Laurent Pharmaceuticals Inc., H1 2016 23 Pipeline by Merck & Co., Inc., H1 2016 24 Pipeline by Merck KGaA, H1 2016 25 Dormant Projects, H1 2016 34 Discontinued Products, H1 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.